larotrectinib
Generic: LAROTRECTINIB SULFATE·Brand: VITRAKVI, Vitrakvi·Code: LOXO-101
larotrectinib: developed by 2 companies · 1 clinical trial tracked.
larotrectinib evidence translation
What we can confirm
1 tracked trial
What it means
More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about larotrectinib, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
cancerunresectable or metastatic solid tumors with NTRK-fusion proteinsBreast CarcinomaCervical CarcinomaColorectal CarcinomaEndometrial CarcinomaGliomaLung Carcinoma
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| ARRAY BIOPHARMA INC (ARRY) | Phase 2 |
| LOXO ONCOLOGY, INC. (LOXO) unresectable or metastatic solid tumors with NTRK-fusion pro… | BLA Filed |
Clinical Trials (1)
Molecular Analysis for Therapy Choice (MATCH)
Primary endpoint: Objective response rate (ORR)
Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)
Frequently asked questions
Who is developing larotrectinib?
larotrectinib is being developed by ARRAY BIOPHARMA INC, LOXO ONCOLOGY, INC..
How many clinical trials involve larotrectinib?
BioSniper tracks 1 clinical trial involving larotrectinib.